A Phase 1/2 interventional study of BI 764524 and Sham control of BI 764524 in Diabetic Retinopathy, sponsored by Boehringer Ingelheim. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.
Sponsored by Boehringer Ingelheim · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 55 under way, 6 of them phase 3. Diabetic Retinopathy · United States.
Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 115th largest by enrollment of the 196 interventional ones that give a count, is one of 17 that started in 2020, is one of 8 in phase 1/2, and was the 166th registered.
779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 22+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Israel and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 1 more country
Ages 18+
Digital Diagnostics, Inc. · Sites in United States
Ages 22+ · Healthy volunteers
BioAge Labs, Inc. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
267 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 64 · Phase 3 35 · Phase 4 20
First in 1992; this study’s year is marked. 17 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 72 across the 196 interventional studies, 161 across the 70 observational. Of the 187 that completed or were terminated, 66 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
114 of 267 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 4 studies filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
19 of the studies in Diabetic Retinopathy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07235085Phase 3Ocular Therapeutix, Inc.A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | 2027-03 |
| NCT06191094University of Colorado, DenverPre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy | 2026-12 |
| NCT04008121MediBeaconFeasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium | 2026-12 |
| NCT07891910Retina Consultants of DelmarvaIopidine to Decrease Intraocular Pressure Rise After Injections | 2026-12-01 |
| NCT05463289Johns Hopkins UniversityACCESS 2: AI for pediatriC diabetiC Eye examS Study 2 | 2026-12-30 |
Add all 19 to your calendar (.ics) → With an account.
Among the 267 studies in Diabetic Retinopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study. The laser treatment is called panretinal photocoagulation.
The purpose of the study is to find out how well different doses of a medicine called BI 764524 are tolerated. BI 764524 is injected into the eye. The study has 2 parts. In the first part, participants get different doses of BI 764524 only once. Participants are in the first part for about 5 months and visit the study site about 8 times. In the second part, participants are put into different groups by chance. Some participants get BI 764524 injections every 4 weeks. Other participants get sham injections every 4 weeks. A sham injection means that it is not a real injection and contains no medicine. Participants cannot tell whether they get the real injection or a sham injection. For the second part, participants are in the study for about 7 months. During this time, they visit the study site about 7 times. In this study, BI 764524 is given to humans for the first time.
The doctors compare how well people tolerate the BI 764524 injections and the sham injections.
The doctors also regularly check the general health of the participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Single rising dose (SRD) and multiple dosing (MD) part:
Women of (WOCBP) and men able to father a child must be ready and able to use two methods of with at least one of them being a highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information and in the clinical trial protocol.
--A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 2 years without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 2 years of menorrhea, a single FSH measurement is sufficient.
SRD part only:
MD part only:
Exclusion Criteria:
SRD part only:
Further exclusion criteria apply.
MD part only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of low dose BI 764524.
Drug: BI 764524
Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of medium dose BI 764524.
Drug: BI 764524
Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of high dose BI 764524.
Drug: BI 764524
Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received three sham intravitreal injections, each separated by 4 weeks.
Drug: Sham control of BI 764524
Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received three intravitreal injections of high dose BI 764524, each separated by 4 weeks.
Drug: BI 764524
BI 764524
Sham control of BI 764524
Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8
Single-rising dose (SRD) part - The number of patients with dose limiting events (DLEs) from drug administration until Day 8 (7 days after treatment).
Time frame: From drug administration (day 1) till day 8, Up to 7±2 days.
Multiple Dosing (MD) Part - the Number of Patients With Drug-related Adverse Events (AEs) From Drug Administration Until End of Trial.
Multiple dosing (MD) part - the number of patients with drug-related Adverse Events (AEs) from drug administration until End of Trial.
Time frame: From drug administration (day 1) till End of Trial, up to 23 weeks.
SRD Part - Number of Patients With Drug-related Adverse Events at End of Trial
SRD part - Number of patients with drug-related Adverse Events at End of Trial.
Time frame: From drug administration (day 1) till End of Trial, up to 15 weeks.
SRD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial
SRD part - Number of patients with ocular Adverse Events (eye disorders) at End of Trial.
Time frame: From drug administration (day 1) till End of Trial, up to 15 weeks.
MD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial
MD part - Number of patients with ocular Adverse Events (eye disorders) at End of Trial.
Time frame: From drug administration (day 1) till End of Trial, up to 23 weeks.
MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 5
MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in full thickness retina (FTR) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].
Time frame: Baseline (day 0) and Visit 5 (day 85±7).
MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 5
MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in superficial vascular complex (SVC) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].
Time frame: Baseline (day 0) and Visit 5 (day 85±7).
MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 7
MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in full thickness retina (FTR) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].
Time frame: Baseline (day 0) and Visit 7 (day 155±7).
MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 7
MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in superficial vascular complex (SVC) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].
Time frame: Baseline (day 0) and Visit 7 (day 155±7).
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 3
Change from baseline of best corrected visual acuity (BCVA) at Visit 3. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 3 data\].
Time frame: Baseline (day 0) and Visit 3 (day 29±7).
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 4
Change from baseline of best corrected visual acuity (BCVA) at Visit 4. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 4 data\].
Time frame: Baseline (day 0) and Visit 4 (day 57±7).
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 5
Change from baseline of best corrected visual acuity (BCVA) at Visit 5. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 5 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 5 data\].
Time frame: Baseline (day 0) and Visit 5 (day 85±7).
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 6
Change from baseline of best corrected visual acuity (BCVA) at Visit 6. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 6 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 6 data\].
Time frame: Baseline (day 0) and Visit 6 (day 113±7).
MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 7
Change from baseline of best corrected visual acuity (BCVA) at Visit 7. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 7 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 7 data\].
Time frame: Baseline (day 0) and Visit 7 (day 155±7).
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 3
MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 3. Results calculated as \[Baseline data\]-\[Visit 3 data\].
Time frame: Baseline (day 0) and Visit 3 (day 29±7).
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 4
MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 4. Results calculated as \[Baseline data\]-\[Visit 4 data\].
Time frame: Baseline (day 0) and Visit 4 (day 57±7)
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 5
MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].
Time frame: Baseline (day 0) and Visit 5 (day 85±7).
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 6
MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 6. Results calculated as \[Baseline data\]-\[Visit 6 data\].
Time frame: Baseline (day 0) and Visit 6 (day 113±7).
MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 7
MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].
Time frame: Baseline (day 0) and Visit 7 (day 155±7).
This was a trial consisting of a non-randomised, uncontrolled, open label single-rising dose part and a randomised, shamcontrolled, single-blind multiple dosing part.
| Milestone | Single-rising Dose Part - Low Dose BI 764524 | Single-rising Dose Part - Medium Dose BI 764524 | Single-rising Dose Part - High Dose BI 764524 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|---|---|---|
| Started | 3 | 3 | 7 | 10 | 22 |
| Treated | 3 | 3 | 6 | 10 | 21 |
| Completed | 3 | 3 | 6 | 7 | 20 |
| Not completed | 0 | 0 | 1 | 3 | 2 |
| Withdrew: Not treated | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other than listed | 0 | 0 | 0 | 1 | 0 |
Single-rising dose (SRD) part - The number of patients with dose limiting events (DLEs) from drug administration until Day 8 (7 days after treatment).
| Participants | Single-rising Dose Part - Low Dose BI 764524 | Single-rising Dose Part - Medium Dose BI 764524 | Single-rising Dose Part - High Dose BI 764524 |
|---|---|---|---|
| Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8 | 0 | 0 | 0 |
Multiple dosing (MD) part - the number of patients with drug-related Adverse Events (AEs) from drug administration until End of Trial.
| Participants | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| Multiple Dosing (MD) Part - the Number of Patients With Drug-related Adverse Events (AEs) From Drug Administration Until End of Trial. | 0 | 2 |
SRD part - Number of patients with drug-related Adverse Events at End of Trial.
| Participants | Single-rising Dose Part - Low Dose BI 764524 | Single-rising Dose Part - Medium Dose BI 764524 | Single-rising Dose Part - High Dose BI 764524 |
|---|---|---|---|
| SRD Part - Number of Patients With Drug-related Adverse Events at End of Trial | 0 | 0 | 0 |
SRD part - Number of patients with ocular Adverse Events (eye disorders) at End of Trial.
| Participants | Single-rising Dose Part - Low Dose BI 764524 | Single-rising Dose Part - Medium Dose BI 764524 | Single-rising Dose Part - High Dose BI 764524 |
|---|---|---|---|
| SRD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial | 2 | 0 | 3 |
MD part - Number of patients with ocular Adverse Events (eye disorders) at End of Trial.
| Participants | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial | 4 | 4 |
MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in full thickness retina (FTR) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].
| Millimeter^2 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 5 | 0.0167 ± 0.0197 | -0.0004 ± 0.0381 |
MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in superficial vascular complex (SVC) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].
| Millimeter^2 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 5 | 0.0489 ± 0.0740 | 0.0741 ± 0.1130 |
MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in full thickness retina (FTR) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].
| Millimeter^2 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 7 | 0.0133 ± 0.0152 | -0.0027 ± 0.0345 |
MD part - Change from baseline of the size of the foveal avascular zone (FAZ) in optical coherence tomography angiography (OCTA) in superficial vascular complex (SVC) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].
| Millimeter^2 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 7 | 0.1233 ± 0.1473 | 0.1101 ± 0.1445 |
Change from baseline of best corrected visual acuity (BCVA) at Visit 3. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 3 data\].
| Number of letters | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 3 | 1.5 ± 13.5 | 1.1 ± 5.2 |
Change from baseline of best corrected visual acuity (BCVA) at Visit 4. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 4 data\].
| Number of letters | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 4 | -4.1 ± 24.4 | 1.4 ± 6.0 |
Change from baseline of best corrected visual acuity (BCVA) at Visit 5. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 5 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 5 data\].
| Number of letters | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 5 | 3.9 ± 10.7 | 2.5 ± 6.5 |
Change from baseline of best corrected visual acuity (BCVA) at Visit 6. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 6 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 6 data\].
| Number of letters | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 6 | 2.6 ± 9.6 | 3.1 ± 9.8 |
Change from baseline of best corrected visual acuity (BCVA) at Visit 7. BCVA was measured using the early treatment diabetic retinopathy study (ETDRS) visual acuity (VA) chart starting at a test distance of 7 meter. The BCVA score was the number of letters read correctly by the patient. Results calculated as \[Baseline data\]-\[Visit 7 data\].
| Number of letters | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of Best Corrected Visual Acuity (BCVA) at Visit 7 | 4.9 ± 9.3 | 3.4 ± 7.5 |
MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 3. Results calculated as \[Baseline data\]-\[Visit 3 data\].
| Micrometer | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 3 | 1.6 ± 4.9 | 0.9 ± 7.2 |
MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 4. Results calculated as \[Baseline data\]-\[Visit 4 data\].
| Micrometer | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 4 | -1.7 ± 5.1 | 0.2 ± 7.2 |
MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 5. Results calculated as \[Baseline data\]-\[Visit 5 data\].
| Micrometer | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 5 | -2.9 ± 5.3 | 3.9 ± 12.8 |
MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 6. Results calculated as \[Baseline data\]-\[Visit 6 data\].
| Micrometer | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 6 | -3.0 ± 3.8 | 8.6 ± 25.1 |
MD part - Change from baseline of central retinal thickness (CRT) in Spectral domain optical coherence tomography (SD-OCT) at Visit 7. Results calculated as \[Baseline data\]-\[Visit 7 data\].
| Micrometer | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|
| MD Part - Change From Baseline of Central Retinal Thickness (CRT) at Visit 7 | -3.2 ± 7.4 | 3.5 ± 9.5 |
Collected over From time of administration till the End of Trial, up to 15 weeks for the SRD part and up to 23 weeks for the MD part.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single-rising Dose Part - Low Dose BI 764524 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Single-rising Dose Part - Medium Dose BI 764524 | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Single-rising Dose Part - High Dose BI 764524 | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Multiple Dosing Part - Sham | 0/10 (0%) | 3/10 (30%) | 6/10 (60%) |
| Multiple Dosing Part - High Dose BI 764524 | 0/21 (0%) | 2/21 (9.5%) | 6/21 (28.6%) |
| Event | Single-rising Dose Part - Low Dose BI 764524 | Single-rising Dose Part - Medium Dose BI 764524 | Single-rising Dose Part - High Dose BI 764524 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|---|---|---|
| Vitreous haemorrhageEye disorders | 0/3 | 0/3 | 0/6 | 2/10 | 0/21 |
| Localised infectionInfections and infestations | 0/3 | 0/3 | 1/6 | 0/10 | 0/21 |
| Peripheral vascular disorderVascular disorders | 0/3 | 0/3 | 1/6 | 0/10 | 0/21 |
| Chronic kidney diseaseRenal and urinary disorders | 0/3 | 0/3 | 0/6 | 1/10 | 0/21 |
| Injection site inflammationGeneral disorders | 0/3 | 0/3 | 0/6 | 0/10 | 1/21 |
| Streptococcal sepsisInfections and infestations | 0/3 | 0/3 | 0/6 | 0/10 | 1/21 |
| EmbolismVascular disorders | 0/3 | 0/3 | 0/6 | 0/10 | 1/21 |
| Event | Single-rising Dose Part - Low Dose BI 764524 | Single-rising Dose Part - Medium Dose BI 764524 | Single-rising Dose Part - High Dose BI 764524 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 |
|---|---|---|---|---|---|
| VertigoEar and labyrinth disorders | 1/3 | 0/3 | 0/6 | 0/10 | 0/21 |
| Conjunctival haemorrhageEye disorders | 1/3 | 0/3 | 0/6 | 1/10 | 0/21 |
| Ocular hyperaemiaEye disorders | 1/3 | 0/3 | 0/6 | 0/10 | 0/21 |
| Vitreous detachmentEye disorders | 0/3 | 0/3 | 2/6 | 0/10 | 0/21 |
| Oedema peripheralGeneral disorders | 1/3 | 0/3 | 0/6 | 0/10 | 0/21 |
| Blood glucose decreasedInvestigations | 1/3 | 0/3 | 0/6 | 0/10 | 0/21 |
| Intraocular pressure increasedInvestigations | 1/3 | 0/3 | 0/6 | 2/10 | 0/21 |
| Lipase increasedInvestigations | 0/3 | 1/3 | 0/6 | 1/10 | 0/21 |
| DizzinessNervous system disorders | 0/3 | 1/3 | 0/6 | 0/10 | 0/21 |
| HypertensionVascular disorders | 1/3 | 0/3 | 1/6 | 0/10 | 1/21 |
Treated set: all patients who were randomised and treated with at least one dose of study drug.
| Age, Continuous(years) | Single-rising Dose Part - Low Dose BI 764524 | Single-rising Dose Part - Medium Dose BI 764524 | Single-rising Dose Part - High Dose BI 764524 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 | Total |
|---|---|---|---|---|---|---|
| Mean | 64.7 ± 15.0 | 61.0 ± 7.0 | 60.8 ± 6.0 | 60.0 ± 6.5 | 59.3 ± 13.2 | 60.2 ± 10.6 |
| Sex: Female, Male(Participants) | Single-rising Dose Part - Low Dose BI 764524 | Single-rising Dose Part - Medium Dose BI 764524 | Single-rising Dose Part - High Dose BI 764524 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 2 | 2 | 5 | 10 | 21 |
| Male | 1 | 1 | 4 | 5 | 11 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Single-rising Dose Part - Low Dose BI 764524 | Single-rising Dose Part - Medium Dose BI 764524 | Single-rising Dose Part - High Dose BI 764524 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 3 | 4 | 2 | 10 |
| Not Hispanic or Latino | 3 | 2 | 3 | 6 | 19 | 33 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Single-rising Dose Part - Low Dose BI 764524 | Single-rising Dose Part - Medium Dose BI 764524 | Single-rising Dose Part - High Dose BI 764524 | Multiple Dosing Part - Sham | Multiple Dosing Part - High Dose BI 764524 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 0 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 3 | 4 |
| White | 1 | 2 | 6 | 9 | 17 | 35 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).For more details refer to: https://www.mystudywindow.com/msw/datasharing
Ran from Jun 2020 to primary completion in Apr 2023, 34 months.
Results were first posted in May 2024, 1 year after primary completion. A results delay was requested in Jul 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.